FDA shoots down weight loss drug targeted at cannabanoid receptors

One of my colleagues had this to say about the much heralded weight loss drug, Acomplia: "If smoking marijuana makes you feel euphoric because THC stimulates the cannabinoid receptors of the brain, can you imagine how dysphoric a cannabinoid receptor antagonist like Rimonabant (Acomplia) could make you feel?"

Apparently, the FDA agreed -- citing data as which indicated that the drug doubled a patient’s risk of psychological problems, including anxiety, depression, aggression and psychosis; the data reflected an increase in suicidal thinking among users of the drug, and included four patients who did commit suicide while using the drug.

The full article can be found in the NY Times here.